Clinical Trials
90 trialsSUCCESSOR-1
Celgene
DREAMM-20
GlaxoSmithKline
MagnetisMM-30
Pfizer
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
DREAMM 14
GlaxoSmithKline
STOMP
Karyopharm Therapeutics Inc
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
LINKER-AL2
Regeneron Pharmaceuticals
EMBRACE
Ontario Clinical Oncology Group (OCOG)
LINKER-MM1
Regeneron Pharmaceuticals
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
C4 Therapeutics, Inc.
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
MonumenTAL-3
Janssen Research & Development, LLC
MajesTEC-9
Janssen Research & Development, LLC
MagnetisMM-20
Pfizer
MajesTEC-10
Janssen Research & Development, LLC
ADAPT-HEM
Beijing Biotech
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Hangzhou Sumgen Biotech Co., Ltd.
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
SUCCESSOR-2
Bristol-Myers Squibb
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
CLOVER-WaM
Cellectar Biosciences, Inc.
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
KarMMa-2
Celgene
SELVEDge
University of Miami
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
MagnetisMM-9
Pfizer
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
SL4903
Institute of Hematology & Blood Diseases Hospital, China
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited